Anemia due to antineoplastic chemotherapy

This code identifies anemia that develops as a direct consequence of chemotherapy treatment for cancer. It signifies a reduction in red blood cells or hemoglobin levels caused by the cytotoxic effects of antineoplastic agents on bone marrow. This is a common side effect that can impact a patient's quality of life and treatment regimen.

Use this code when documentation clearly states anemia is a direct result of antineoplastic chemotherapy. This typically applies to patients undergoing active cancer treatment who develop new or worsening anemia. Supporting documentation would include physician notes explicitly linking the anemia to chemotherapy, laboratory results showing decreased hemoglobin/hematocrit, and a history of recent or ongoing chemotherapy.

• Do not use this code if the anemia is due to the underlying malignancy itself; instead, consider D63.0.
• Distinguish this from aplastic anemia caused by chemotherapy (D61.1), which involves pancytopenia.
• Always sequence this code after the code for the underlying malignancy and the adverse effect of the antineoplastic drug (T45.1X5-).